Samsung Galaxy Watch Gets Blood Pressure Monitoring in the US, With One Major Caveat

Why It Matters

The addition broadens Samsung’s health‑tech portfolio, but regulatory limits and the cuff requirement may curb rapid consumer uptake, highlighting the competitive gap with Apple’s FDA‑cleared hypertension alerts.

Key Takeaways

• Feature rolls out to Galaxy Watch 4 and Watch 8.
• Requires upper‑arm cuff for calibration and 28‑day recalibration.
• Not FDA‑cleared; intended for wellness, not diagnosis.
• Only works with Samsung phones Android 12+.
• Passive trend monitoring promised later this year.

Pulse Analysis

Wearable health monitoring has moved from novelty to a core selling point for premium smartwatches. Samsung’s decision to finally enable blood‑pressure tracking in the U.S. reflects a broader industry push to embed clinical‑grade metrics into everyday devices. While the feature has been available overseas for years, U.S. regulators have kept it out of the diagnostic realm, forcing Samsung to label it a wellness tool. This cautious approach protects the brand from liability but also signals that the company is still navigating the FDA’s stringent clearance process.

The user experience, however, is far from seamless. Consumers must purchase a conventional upper‑arm cuff, install a separate Health Monitor app, and perform a calibration every four weeks to maintain accuracy. The requirement limits the feature to Galaxy Watch 4 and Watch 8 models paired with Samsung smartphones running Android 12 or higher, excluding other Android devices and the Galaxy Fit line. In contrast, Apple’s recent hypertension alerts are fully FDA‑cleared and operate passively, giving Apple a clear advantage in the health‑focused smartwatch market.

From a market perspective, Samsung’s rollout underscores the competitive arms race in wearable health tech. By offering on‑demand readings now and promising passive trend monitoring later, Samsung aims to close the functional gap with Apple while avoiding regulatory hurdles. If the passive feature delivers reliable trend data, it could boost user engagement and position Samsung as a viable alternative for consumers seeking comprehensive health insights without a medical‑grade device. The next few months will reveal whether the added complexity deters adoption or if the convenience of having blood‑pressure data on the wrist outweighs the extra steps.